What's Going On With Johnson and Johnson Shares Friday?
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy.
强生（纽交所：JNJ）股票在周五出现趋势。在上周，这家药品公司宣布了两项临床试验的积极结果，并获得加拿大卫生部批准与基于铂金的化疗药物RYBREVANt联合使用。
The Details: The first of the two clinical trials is a Phase 3 study regarding the use of nipocalimab for patients with generalized myasthenia gravis.
这两项临床试验中的第一项是一项III期研究，研究nipocalimab用于广泛性重症肌无力患者的使用。
In the first trial, patients who received nipocalimab alongside standard treatment over the course of 24 weeks achieved superiority over the placebo group in activities of daily living. The study achieved its primary endpoint as well as secondary endpoints, such as improvement in strength and function of certain muscle groups.
在第一项试验中，在24周的标准治疗过程中，接受nipocalimab治疗的患者的日常生活活动优于安慰剂组。该研究达到了主要终点和次要终点，例如某些肌肉群的力量和功能改善。
The second study was the Phase 3 CARTITUDE-4 study evaluating CARVYKTI against standard therapies for patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. The interim analysis demonstrated a notable and statistically significant enhancement in overall survival for patients who received CARVYKTI versus standard treatments.
第二项研究是第III期CARTITUDE-4研究，评估CARVYKTI与一线治疗后复发或镰刀状细胞贫血耐药性多发性骨髓瘤的标准治疗对比。中期分析表明，接受CARVYKTI治疗的患者相比标准治疗组在总体生存方面有显著的统计学显著性提高。
"CARVYKTI, a one-time infusion, is now the first cell therapy to significantly improve overall survival versus standard of care for patients with myeloma as early as second line," said Jordan Schecter, M.D., vice president, disease area leader, multiple myeloma, Johnson & Johnson Innovative Medicine.
“CARVYKTI作为一次性输注，现在是针对骨髓瘤患者早期二线治疗而不是标准护理的首个可显著改善总体生存率的细胞疗法，”强生创新药品公司多发性骨髓瘤疾病区域领袖、副总裁乔丹·谢克特博士说。
On Wednesday, Health Canada authorized the use of RYBREVANT in combination with platinum-based chemotherapy for the treatment of certain non-small cell lung cancers.
周三，加拿大卫生部批准RYBREVANt与基于铂金的化疗药物联合用于某些非小细胞肺癌的治疗。
Analyst Changes: Over the past week, one analyst has issued a price target adjustment.
分析师变动：在过去的一周中，有分析师发布了价格目标调整。
- On Monday, Cantor Fitzgerald analyst Louise Chen reiterated Johnson & Johnson with a Overweight and maintained $215 price target.
- 周一，卡内基菲茨杰拉德分析师路易丝·陈重申对强生报告评级为超配，并维持215美元的价格目标。
Related Link: Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
相关链接：激进投资者在运动医学公司Smith＆Nephew中入股，股价飙升。
JNJ Price Action: At the time of writing, Johnson and Johnson stock is trading .57% lower at $144.85, according to data from Benzinga Pro.
JNJ价格走势：截至撰写时，强生股票按$144.85交易，降低了0.57％，数据来源于Benzinga Pro。
Image: Photo via Shutterstock
图像：通过shutterstock拍摄